Bayer has received regulatory approval in China for a new blood-thinning medication aimed at preventing recurrent strokes. This marks the first authorization for a new class of blood-thinning drugs, with the new medication named asundexian, expected to be marketed as Sunharbo.
The approval comes as Bayer looks to sustain its market position following the loss of patent protection for its blockbuster drug, Xarelto. The company has positioned asundexian as a critical component in its strategy to replace revenue from Xarelto, which had generated substantial sales prior to its patent expiration.
Asundexian’s introduction in China represents not only a significant milestone for Bayer but also highlights the growing competition in the anticoagulant market. The company is anticipating that Sunharbo will fulfill an essential need for patients at risk of recurrent strokes, leveraging innovative approaches in treatment.
Details regarding the drug’s pricing and distribution strategy in China have not been fully disclosed, but Bayer’s commitment to addressing the needs of patients who may benefit from this medication remains clear. The company plans to capitalize on the regulatory approval to expand its footprint in the region.
Next steps for Bayer may involve launching marketing initiatives and engaging with healthcare professionals to promote awareness of Sunharbo among potential patients and prescribers in China. The company’s continued investment and focus on cardiovascular health are expected to shape its strategy going forward.
